Nothing Special   »   [go: up one dir, main page]

MX2020008106A - Moduladores del receptor nmda espiro-lactama y usos de los mismos. - Google Patents

Moduladores del receptor nmda espiro-lactama y usos de los mismos.

Info

Publication number
MX2020008106A
MX2020008106A MX2020008106A MX2020008106A MX2020008106A MX 2020008106 A MX2020008106 A MX 2020008106A MX 2020008106 A MX2020008106 A MX 2020008106A MX 2020008106 A MX2020008106 A MX 2020008106A MX 2020008106 A MX2020008106 A MX 2020008106A
Authority
MX
Mexico
Prior art keywords
nmda receptor
spiro
receptor modulators
lactam nmda
lactam
Prior art date
Application number
MX2020008106A
Other languages
English (en)
Inventor
M Amin Khan
Original Assignee
Aptinyx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aptinyx Inc filed Critical Aptinyx Inc
Publication of MX2020008106A publication Critical patent/MX2020008106A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos que tienen potencia en la modulación de actividad del receptor NMDA. Tales compuestos pueden ser útiles en el tratamiento de afecciones tal como depresión y trastornos relacionados así como otros trastornos.
MX2020008106A 2018-01-31 2019-01-31 Moduladores del receptor nmda espiro-lactama y usos de los mismos. MX2020008106A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862624218P 2018-01-31 2018-01-31
US201862718107P 2018-08-13 2018-08-13
PCT/US2019/016098 WO2019152678A1 (en) 2018-01-31 2019-01-31 Spiro-lactam nmda receptor modulators and uses thereof

Publications (1)

Publication Number Publication Date
MX2020008106A true MX2020008106A (es) 2020-09-25

Family

ID=65494516

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008106A MX2020008106A (es) 2018-01-31 2019-01-31 Moduladores del receptor nmda espiro-lactama y usos de los mismos.

Country Status (15)

Country Link
US (1) US20210047324A1 (es)
EP (1) EP3746442A1 (es)
JP (2) JP2021512109A (es)
KR (1) KR20200115610A (es)
CN (1) CN112218866A (es)
AU (1) AU2019215049A1 (es)
BR (1) BR112020015666A2 (es)
CA (1) CA3089559A1 (es)
CL (1) CL2020001990A1 (es)
IL (1) IL276330A (es)
MX (1) MX2020008106A (es)
PE (1) PE20211455A1 (es)
PH (1) PH12020551140A1 (es)
SG (1) SG11202007251XA (es)
WO (1) WO2019152678A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2951183T (pt) 2013-01-29 2019-06-17 Aptinyx Inc Moduladores espirolactamas de um recetor nmda e as suas utilizações
KR102538803B1 (ko) 2016-08-01 2023-06-01 앱티닉스 인크. 스피로-락탐 nmda 조정제 및 그의 사용 방법
KR102465757B1 (ko) 2016-08-01 2022-11-09 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
US11299495B2 (en) 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
KR102503590B1 (ko) 2016-08-01 2023-02-24 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
CA3089561A1 (en) 2018-01-31 2019-08-08 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
CA3092470A1 (en) 2018-02-27 2019-09-06 Incyte Corporation Imidazopyrimidines and triazolopyrimidines as a2a / a2b inhibitors
WO2019222677A1 (en) 2018-05-18 2019-11-21 Incyte Corporation Fused pyrimidine derivatives as a2a / a2b inhibitors
GEP20237560B (en) 2018-07-05 2023-10-25 Incyte Corp Fused pyrazine derivatives as a2a / a2b inhibitors
TWI829857B (zh) 2019-01-29 2024-01-21 美商英塞特公司 作為a2a / a2b抑制劑之吡唑并吡啶及三唑并吡啶
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
WO2024054919A1 (en) * 2022-09-08 2024-03-14 Tenacia Biotechnology (Hong Kong) Co., Limited Spiro-lactam nmda receptor modulators and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2515615C2 (ru) * 2008-09-18 2014-05-20 Нортвестерн Юниверсити Модуляторы нмда-рецептора и их применения
TWI466885B (zh) * 2009-07-31 2015-01-01 Japan Tobacco Inc 含氮螺環化合物及其醫藥用途
CA2789331C (en) * 2010-02-11 2017-11-07 Northwestern University Secondary structure stabilized nmda receptor modulators and uses thereof
CN102267995A (zh) * 2010-06-04 2011-12-07 艾琪康医药科技（上海）有限公司 一种制备二氮杂螺环化合物的方法
EA031905B1 (ru) * 2013-01-29 2019-03-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
CA2899191A1 (en) * 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
JP2016506961A (ja) * 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
US9828384B2 (en) * 2013-01-29 2017-11-28 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
PT2951183T (pt) * 2013-01-29 2019-06-17 Aptinyx Inc Moduladores espirolactamas de um recetor nmda e as suas utilizações
US10525036B2 (en) * 2015-04-03 2020-01-07 Recurium Ip Holdings, Llc Spirocyclic compounds
CA3024606C (en) * 2016-05-19 2019-09-03 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
WO2017201285A1 (en) * 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
US11299495B2 (en) * 2016-08-01 2022-04-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
WO2018153849A1 (en) * 2017-02-21 2018-08-30 Sanofi Azetidine compounds as gpr119 modulators for the treatment of diabetes, obesity, dyslipidemia and related disorders
JP2022092387A (ja) * 2020-12-10 2022-06-22 キヤノン株式会社 画像形成装置

Also Published As

Publication number Publication date
US20210047324A1 (en) 2021-02-18
WO2019152678A1 (en) 2019-08-08
SG11202007251XA (en) 2020-08-28
BR112020015666A2 (pt) 2021-02-23
CA3089559A1 (en) 2019-08-08
KR20200115610A (ko) 2020-10-07
CN112218866A (zh) 2021-01-12
JP2024019396A (ja) 2024-02-09
CL2020001990A1 (es) 2021-03-26
EP3746442A1 (en) 2020-12-09
PE20211455A1 (es) 2021-08-05
IL276330A (en) 2020-09-30
JP2021512109A (ja) 2021-05-13
AU2019215049A1 (en) 2020-09-17
PH12020551140A1 (en) 2021-05-31

Similar Documents

Publication Publication Date Title
PH12020551140A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020551144A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12020550523A1 (en) Modulators of the integrated stress pathway
PH12018502438A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12021552759A1 (en) Substituted cycloalkyls as modulators of the integrated stress pathway
MX2019001223A (es) Moduladores de receptores de quimioquina y usos de los mismos.
PH12019500208A1 (en) Spiro-lactam nmda receptor modulators and methods of using same
MX2021013193A (es) Cicloalquilos sustituidos como moduladores de la vía integrada del estrés.
AU2017261336A1 (en) Modulators of the integrated stress pathway
AU2017260367A1 (en) Modulators of the integrated stress pathway
MX2020007812A (es) Moduladores del receptor de quimiocina y usos de los mismos.
AU2017260374A1 (en) Modulators of the integrated stress pathway
PH12019500202A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12019500207A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
MX2020012823A (es) Alcoxipiridinil indolsulfonamidas sustituidas.
MX2019000588A (es) Moduladores de la somatostatina y usos de los mismos.
MX2018009752A (es) 1,2,3,-triazoles sustituidos como moduladores de nmda selectivos de nr2b.
MX2019010949A (es) Moduladores de somatostatina y usos de los mismos.
PH12019500206A1 (en) Spiro-lactam nmda receptor modulators and uses thereof
PH12022550165A1 (en) Interleukin-2 agents and uses thereof
MX2021015500A (es) Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b.
MX2019001322A (es) Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
JOP20210330A1 (ar) مركبات بيرازولو-بيريدين عطرية غير متجانسة مستبدلة واستخدامها كمعدِّلات لمستقبل الغلوتومات "glun2b"
CR20210580A (es) Amidas depirazol-piridina sustituidos y su uso como moduladores del receptor glun2b
EP3976182A4 (en) MODULATION OF THE EFFECTS OF GAMMA CYTOKINE SIGNALING FOR THE TREATMENT OF ALOPECIA AND ALOPECIA-ASSOCIATED DISORDERS